BD LSR II Flow Cytometer

描述(由申请人提供)：多参数流式细胞术已被证明是芝加哥大学许多生物和医学研究领域不可或缺的工具。能够以精确和快速的方式识别和计数单个活细胞，使得能够从任何数量的组织和器官中确定稀有细胞类型的特征。检测这类事件的能力对于癌症和免疫介导性疾病的研究尤为关键。以前，多参数流式细胞仪已经能够识别许多这样的细胞类型；然而，在许多商业仪器上，荧光检测已经达到了极限。在干细胞研究和造血领域，解决抗原表达非常低的细胞类型的必要性已经变得显而易见。因此，显然，能够以高吞吐量同时检测多个参数的仪器，以及能够分辨这些微弱荧光细胞亚型的仪器，对于芝加哥大学的研究的持续推进是必要的。新的高灵敏度、4激光器、14参数BD LSRII将支持这些检测标准，还将缓解用户群目前面临的一些容量问题。当前设施的LSRII使用量增加了15%，而青色ADP的丢失迫使设施开始租赁所需的LSRII。因此，对这项提议进行了修订，要求提供资金买断租用的仪器，以便主要调查员可以继续进行研究。NIH资助的12个主要用户的项目集中在各种各样的生物医学科学上，包括造血、哮喘、宿主防御、肺损伤、移植、自身免疫性疾病以及基础癌症和免疫学研究，将依赖于该仪器。该仪器的使用效率将通过将其放置在芝加哥大学校园内的流式细胞术核心设施中而得到帮助。通过将该仪器放置在校园内已建立的核心设施(Serving&>80 PI‘s)中，教职员工将能够利用设施主管和工作人员在其操作和使用方面的专业知识。此外，在核心设施中，所有大学调查人员都可以平等进入。因此，该仪器将极大地帮助芝加哥大学缓解当前的容量问题，并提供最先进的技术，使我们的研究人员保持在他们研究的前沿。公共卫生相关性：美国国立卫生研究院资助的12个项目将在很大程度上依赖于所要求的仪器，这些项目侧重于造血、哮喘、宿主防御、肺损伤、移植、自身免疫性疾病、癌症机制和免疫学等生物医学研究领域。在所请求的仪器上采用的最先进技术将有助于揭示回答这些重要问题所需的信息。

DESCRIPTION (provided by applicant): Multiparametric flow cytometry has proven to be an indispensable tool for numerous areas of biological and medical research at the University of Chicago. The ability to identify and enumerate individual living cells in a precise and rapid fashion has allowed for the characterization of rare cell types from any number of tissues and organs. The ability to detect such events is particularly crucial for the study of cancer and immune-mediated diseases. Previously, multiparametric flow cytometers have been able to identify many such cell types; however the limits of fluorescence detection have been reached on many commercial instruments. The necessity to resolve cell types with very low antigen expression has become evident in the area of stem cell research and hematopoiesis. Therefore, it is evident that instrumentation that will be able to detect multiple parameters simultaneously at high through-put rates, and also resolve these dimly fluorescent cell subtypes, is necessary for the continued advancement of the research at the University of Chicago. A new, high sensitivity, 4-laser, 14-parameter BD LSRII will allow for these detection criterion, and also alleviate some of the capacity issues currently experienced by the user base. A 15% increase in usage of the current facility's LSRII and the loss of the Cyan-ADP has forced the facility to begin leasing the requested LSRII. As such this proposal has been revised to request funding to buyout the leased instrument so that the major investigators may continue to perform their studies. Twelve major users with as many NIH funded projects focusing on a wide variety of biomedical science including hematopoiesis, asthma, host defense, lung injury, transplantation, autoimmune diseases as well as basic cancer and immunology research, will depend on this instrumentation. The efficiency of the usage of this instrument will be aided by its placement in the University of Chicago Flow Cytometry Core Facility on campus. By placing this instrument in the already established core facility on campus (serving >80 PI's), the faculty will be able to exploit the expert knowledge of the facility directors and staff in its operation and usage. Further, in the core facility equal access is provided to all University Investigators. Thus, this instrument will greatly benefit the University of Chicago by easing current capacity issues and providing state-of-the-art technology, allowing our investigators to remain at the forefront of their research. PUBLIC HEALTH RELEVANCE: Twelve NIH funded projects focusing on biomedical research areas such as hematopoiesis, asthma, host defense, lung injury, transplantation, autoimmune diseases, mechanisms of cancer and immunology will rely heavily on the requested instrumentation. State-of-the-art technologies employed on the requested instrument will help unveil the information necessary to answer these important questions.